Ernexa Therapeutics Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
ERNA · Price history
Price at last available close
$1.99
−$1.48 (-42.65%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Ernexa Therapeutics Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
How they make money
Ernexa Therapeutics Inc. is a preclinical-stage biotechnology company focused on the development of synthetic allogeneic iMSC therapies for autoimmune diseases. As a preclinical entity, the company does not currently generate revenue from product sales and relies on capital raises and financing activities to fund its research, development, and clinical trial operations.
Products & services
The company is developing ERNA-101, a synthetic allogeneic iMSC therapy candidate currently in preclinical development for the treatment of autoimmune diseases.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- Brookline Capital Markets — Engaged as a placement agent for the company's securities offerings.Source
Strengths
- Experienced management teamSource
Company-specific research
Questions worth answering for ERNA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can ERNA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ERNA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ERNA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ERNA's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of ERNA's score?
Essential Investment Snapshot
Market Cap
$3.3M
P/E Ratio
-0.2
EPS
$-18.85
52-Week High
$71.50
52-Week Low
$3.04
Beta
2.62
Shares Outstanding
1.6M
Total Debt
$349K
Dividend
No current dividend
Liquidation Value / Share
$1.96
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ERNA
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-345.1x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on ERNA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Experienced management team.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Preclinical stage of development and lack of operating history.
- −Requirement for significant additional capital to fund operations.
- −Regulatory risks associated with FDA approval processes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$1.99
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +755.9%
Revenue changed sharply from 2023 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $582K | $68K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $0.00 | $96K | $236K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | $0.00 | $486K | -$168K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $4.2M | $4.6M | $5.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $5.2M | $13.1M | $14.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $9.3M | $16.2M | $21.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$13.8M | -$36.1M | -$19.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$9.3M | -$15.7M | -$21.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $27K | $6.8M | $614K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$14.1M | -$44.5M | -$21.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | -$45K | $30K | -$3K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$14.1M | -$44.5M | -$21.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-56.00 | $-39.25 | $-102.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 1.18M | 252K | 1.14M | 213K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 1.18M | 252K | 1.14M | 213K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$3.40
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-41.1%
Cash Change
+16.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 77.7%. Cash increased 16.5%. Total debt declined 41.1%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Rumor Mill · ERNA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial